Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IMVT - Immunovant Inc


IEX Last Trade
30.93
-0.050   -0.162%

Share volume: 658,055
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$30.98
-0.05
-0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 3%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-4.69%
1 Month
7.25%
3 Months
17.00%
6 Months
-17.95%
1 Year
38.38%
2 Year
496.53%
Key data
Stock price
$30.93
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$19.50 - $45.58
52 WEEK CHANGE
$0.29
MARKET CAP 
4.523 B
YIELD 
N/A
SHARES OUTSTANDING 
146.367 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$589,819
AVERAGE 30 VOLUME 
$783,412
Company detail
CEO:
Region: US
Website: immunovant.com
Employees: 144
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.

Recent news